IPO Lockup Expiration Alert: Pandion Therapeutics

IPO锁定到期警报:Pandion Therapeutics

2021-01-14 00:36:37 RTTNews


The lockup period of Watertown, Massachusetts-based Pandion Therapeutics expires tomorrow . Pandion Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for patients suffering from autoimmune diseases. The company's lead product candidate is PT101, for which a phase 1a/2b clinical trial in ulcerative colitis is expected to start in mid-2021 and phase II clinical trial in systemic lupus erythematosus is expected to start in the second half 2021. Also in the pipeline are a couple of compounds in pre-clinical testing like PT627 for the treatment of autoimmune disease, and PT002 and PT001, for the treatment of gastrointestinal and liver diseases. Pandion Therapeutics made its debut on The Nasdaq Global Select Market on July 17, 2020, offering its shares at a price of $18 each and as mentioned above, the 180 day lockup period expires on January 13. PAND opened the first day of trading on July 17 at $27.00 and closed at $18.10 that day. The stock has thus far hit a low of $10.28 and a high of $27.75. PAND closed Tuesday's trading at $18.01, up 5.32%. In after hours trading, the stock was down 0.61% to $17.90. For comments and feedback contact: editorial@rttnews.com Business News
总部位于马萨诸塞州沃特敦的Pandion Therapeutics公司的禁闭期将于明天到期。 Pandion Therapeutics是一家临床阶段的生物制药公司,为患有自身免疫性疾病的患者开发新的疗法。 公司的主导产品候选为PT101,其在溃疡性结肠炎方面的1a/2B期临床试验预计将于2021年中期开始,在系统性红斑狼疮方面的II期临床试验预计将于2021年下半年开始。 另外还有两种化合物正在进行临床前试验,如用于治疗自身免疫性疾病的PT627,以及用于治疗胃肠道和肝脏疾病的PT002和PT001。 Pandion Therapeutics于2020年7月17号首次在纳斯达克全球精选市场上市,以每股18英镑的价格发售股份,如上所述,180天的锁定期将于1月13日到期。 PAND于7月17日以27.00开市首日交易,当天以18.10收盘。该股迄今最低触及10.28点,最高触及27.75点。 PAND周二收盘报18.01点,上涨5.32%。盘后交易中,该股下跌0.61%,至17.90点。 如需评论和反馈,请联系:editorial@rttnews.com 商业新闻